Acadia Healthcare Company, Inc. (NASDAQ:ACHC) Shares Sold by Xponance Inc.

Xponance Inc. decreased its holdings in shares of Acadia Healthcare Company, Inc. (NASDAQ:ACHC) by 9.1% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,864 shares of the company’s stock after selling 985 shares during the quarter. Xponance Inc.’s holdings in Acadia Healthcare were worth $666,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Blue Trust Inc. boosted its stake in Acadia Healthcare by 86.1% in the 2nd quarter. Blue Trust Inc. now owns 536 shares of the company’s stock worth $36,000 after buying an additional 248 shares during the last quarter. Mather Group LLC. acquired a new position in Acadia Healthcare during the first quarter worth approximately $48,000. nVerses Capital LLC purchased a new position in Acadia Healthcare during the second quarter worth approximately $95,000. Innealta Capital LLC acquired a new position in shares of Acadia Healthcare in the 2nd quarter valued at $164,000. Finally, Capstone Investment Advisors LLC purchased a new stake in shares of Acadia Healthcare during the 4th quarter valued at $204,000.

Acadia Healthcare Trading Down 16.4 %

NASDAQ ACHC opened at $63.28 on Monday. The company’s fifty day simple moving average is $74.23 and its 200-day simple moving average is $71.62. The stock has a market cap of $5.87 billion, a P/E ratio of -452.00, a PEG ratio of 2.19 and a beta of 1.30. Acadia Healthcare Company, Inc. has a 52 week low of $53.22 and a 52 week high of $87.77. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.60.

Acadia Healthcare (NASDAQ:ACHC) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.87 by $0.04. Acadia Healthcare had a negative net margin of 0.17% and a positive return on equity of 11.42%. The company had revenue of $796.00 million during the quarter, compared to analysts’ expectations of $784.38 million. During the same period in the prior year, the company posted $0.92 EPS. The firm’s revenue for the quarter was up 8.8% on a year-over-year basis. Equities research analysts predict that Acadia Healthcare Company, Inc. will post 3.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ACHC has been the topic of a number of research analyst reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $94.00 target price on shares of Acadia Healthcare in a report on Friday, September 20th. Barclays decreased their target price on Acadia Healthcare from $89.00 to $83.00 and set an “overweight” rating for the company in a report on Thursday, August 1st. Cantor Fitzgerald restated a “neutral” rating and issued a $90.00 price target on shares of Acadia Healthcare in a report on Monday, August 19th. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Acadia Healthcare from $70.00 to $75.00 and gave the stock a “hold” rating in a research note on Friday, August 2nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $87.44.

About Acadia Healthcare

Acadia Healthcare Company, Inc provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities.